General MedicationsOPHTHALMICGeneric

ACUVUE THERAVISION WITH KETOTIFEN

KETOTIFEN FUMARATE

Standard Dose

EQ 19MCG BASE

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview ACUVUE THERAVISION WITH KETOTIFEN is listed in Drugs@FDA under application 022388 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient KETOTIFEN FUMARATE Form and strength DRUG-ELUTING CONTACT LENS;OPHTHALMIC - EQ 19MCG BASE Sponsor JOHNSON JOHNSON VISN Submission history Latest submission status date: 2022-02-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview ACUVUE THERAVISION WITH KETOTIFEN is listed in Drugs@FDA under application 022388 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient KETOTIFEN FUMARATE Form and strength DRUG-ELUTING CONTACT LENS;OPHTHALMIC - EQ 19MCG BASE Sponsor JOHNSON JOHNSON VISN Submission history Latest submission status date: 2022-02-25 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.